ARMPArmata Pharmaceuticals, Inc.vs its industry peers
A metric-by-metric comparison of Armata Pharmaceuticals, Inc. against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARMPEsta | $109M#2 | — | — | — | — | -818.8%#8 | — | — | — | — | — | 0.1%#1 |
| HUMA | $118M#1 | — | 3.8x#5 | 58.0x#4 | — | 72.5%#3 | -5306.0%#4 | -130.6%#6 | — | — | -73.1%#2 | — |
| ATRA | $85M#3 | — | — | 0.7x#2 | -6.3%#3 | 138.3%#1 | 29.7%#1 | — | — | — | — | — |
| TNYA | $84M#4 | — | 1.2x#2 | — | — | 18.5%#5 | — | -130.5%#5 | — | — | — | — |
| VXRT | $80M#5 | 2.0x#1 | 1.0x#1 | 0.3x#1 | 726.7%#1 | 124.4%#2 | 7.6%#2 | 0.0%#1 | 22.5%#1 | — | -24.0%#1 | — |
| CSBR | $68M#6 | — | 17.5x#6 | 1.1x#3 | 4.4%#2 | -125.0%#7 | -1.9%#3 | -0.0%#2 | — | — | — | — |
| CRDF | $66M#7 | — | 2.5x#4 | 112.0x#5 | -13.2%#4 | -0.9%#6 | -8256.3%#5 | -0.2%#3 | — | — | — | — |
| CGTX | $65M#8 | — | 2.0x#3 | — | — | 30.9%#4 | — | -71.1%#4 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-11-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice